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1183. Nothing exasperates a thoracic surgeon more than to be confrontedwith a mesothelioma. Few such cases are diagnosed per year inthe United States, and many of the internists, pulmonologists, andmedical oncologists who see these cases refer them to a thoracicsurgeon for one purpose: palliation. Thoracic surgeons them-selves differ remarkably in their approach to this disease, but the
good news is that there is a cadre of individuals, including Lee and associates,1 who
actually advocate for novel approaches in the management of this beast.
The most objective method to advocate for change in medical practice is to
develop trials that, ideally, will set a new standard of care, and for this disease, the
credibility of any trial is strengthened when a multidisciplinary approach is used. In
this edition of the Journal, Lee and colleagues from the University of California,
San Francisco (UCSF), report a multidisciplinary approach to the management of
malignant pleural mesothelioma using radical pleurectomy/decortication and radi-
ation in 32 patients. This report, although small, is an enlightening representation of
all that is controversial in the care of the patient with the potentially resectable
mesothelioma, and many of these issues involve (1) the goals of an operation, (2)
patient selection, (3) follow-up methods, and (4) choice of adjuvant therapy.
Undoubtedly, there are no standards for these issues that dictate “best practice” for
mesothelioma; however, in dissecting the results and recommendations from the
UCSF study, the informed reader should be presented with alternative explanations
that could be thought provoking.
Goals of the Operation
If mesothelioma is an incurable disease, then what are the goals of an operation in
the first place? As Lee’s group has pointed out, the operation should be a part of a
package of multimodal therapies. The operation performed, however, may depend
on whether the patient is entered into a clinical trial (which specifies or does not
specify the type of operation to be done) or whether the patient is being treated
off-protocol. Once the decision is made that a patient is a candidate for “mesothe-
lioma resection,” the surgeon must, in his or her own mind (and ideally written as
part of the protocol) define the end points of the operation. Obviously, mesothelioma
resections are giant debulkings, cytoreductions, partial resections, or some such
designation, and terms such as R0 and R1 are nice but irrelevant. Isn’t the ultimate
goal of performing an operation for mesothelioma to safely reduce the burden of
disease enough so that tumor cannot be seen at the end of the operation? I realize
that this sounds incredibly naive. However, if the tumor can be made grossly
undetectable and a reproducible way can be found of documenting how much
residual disease is left after the resection, that will at least provide an objective
starting point for each patient so that the degree of cytoreduction is approximately
equal. If you want to be “cute,” the volume of disease can be measured by means
of 3-dimensional reconstructions on the first computed tomographic (CT) scan after
resection, and that relative volume can be recorded for each patient.2 The most
important point, however, is that if the surgeon is confronted with patients of equal
cardiopulmonary demographics that permit either pleurectomy/decortication (P/D)
or extrapleural pneumonectomy (EPP), it does not matter how this cytoreduction is
accomplished: just that it be equal among all individuals and that it be safe. The only
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way in which we will be able to interpret and compare surgi-
cally based studies in mesothelioma will be to confront and
control the heterogeneity of resection results. In fact, the de-
gree of the resection affects the survival of the patients and the
progression of the disease.2 What is equally important for the
surgeon is to recognize early in the course of the dissection that
if these goals cannot be accomplished, then the operation
should be aborted. Location, degree of invasion, inability to
mobilize the tumor safely, or unsuspected extrathoracic spread
are but a few reasons for early termination. Nothing is more
painfully clear from the Lee article than the fact that the only
prognostic variable that correlated with survival was the
amount of intraoperative radiation therapy (IORT) ports that
were necessary. To summarize, the fewer the number of
IORT ports, the greater the survival of the patients, and, in
the authors own words, “An increased number of IORT
fields reflects a greater extent of residual disease, which
might account for the difference in survival.” This agrees
with our own data from the National Institutes of Health that
if the residual volume of tumor seen on the immediate
follow-up CT scan is above a certain threshold, those pa-
tients with the higher volumes have shorter times to progres-
sion and shorter survival times.2 Rusch and Venkatraman3
have also commented on the importance of T status and overall
survival in the disease.
Obviously the goal of the cytoreduction harkens back to
the ovarian analogy (which, curiously, shares a few unique,
overexpressed genes with mesothelioma such as mesothe-
lin4) with the hope that the adjuvant therapies can “mop up”
the microscopic disease. Whether it is intrapleural radiation
therapy with postoperative intensity-modulated radiation
therapy (IMRT) as described by Lee, or intrapleural hyper-
thermic chemoperfusion,7 intrapleural chemo-immunother-
apy,6-8 intrapleural photodynamic therapy,9-13 intrapleural
gene therapy,14 postoperative chemotherapy, or postopera-
tive radiotherapy,15 we all want to reset the clock for the
mesothelioma patient back to a stage I minimal burden of
disease status. This philosophy satisfies the accomplishment
gratification of the surgeon and puts the responsibility on
adjuvants which, as of yet have, not been able to solve the
incredibly complex biology of the disease.
Patient Selection and Type of Operation
All of us can appreciate the difference in homeostatic insults
between pleurectomies and extrapleural pneumonectomies,
and it is admirable that the authors can be so frank to state,
“The decision to perform a lung-preserving procedure in
this group of patients was not based solely on their ability to
tolerate pneumonectomy but rather based on a bias that P/D
is better tolerated in patients with an essentially incurable
disease.” This is a fair and accurate statement if one com-
pares two patients with mesothelioma who have identical
amounts of tumor, whose tumor can be cytoreduced to equal
levels by P/D or by EPP, but one has P/D and the other has
EPP. Without question, the patient who has the P/D will be
functionally superior after the operation compared with the
patient having the EPP. In fact, having a P/D may open up
more experimental protocol options for the patient if the
disease progresses. We are not given the luxury as thoracic
surgeons, however, to have patients who can have mean-
ingful cytoreductions for mesothelioma by P/D in all cases.
If, philosophically, a surgeon believes that an EPP should
not be done on an “incurable” patient, that is a different
matter, and that stance should be respected. This philosophy
will militate that a number of patients with bulky mesothe-
liomas will not qualify for investigational programs because
an EPP would be necessary to accomplish tumor debulking.
Frankly, there is no formula for the appropriate operation
for mesothelioma, and as a mesothelioma surgeon, one does
not have to be wedded to one operation. The surgeon should
do what is necessary to accomplish the goals of the opera-
tion mentioned above while considering the patient’s pre-
operative functional evaluation.
Certainly, selection must play a role in this decision, and
if the patient’s cardiac status is satisfactory, then how does
one decide what will be “better tolerated?” In the literature,
there seems to be a gray zone between the forced expiratory
volume in 1 second of 1.5 L mentioned in the Lee paper and
the figure of 2.0 L, which is quoted by Sugarbaker and
associates.16 Sugarbaker and colleagues, however, stress the
need for quantitative perfusion scanning in patients with
pleural mesothelioma, and others have found that in patients
with bulky disease or combination fluid and bulky disease,
the affected side may contribute next to nothing to the
patients’ pulmonary status. Personally, I am not sure
whether there are any preoperative tests at present that will
help me with 100% certainty to determine which operation
will accomplish these goals short of visual inspection of the
pleural war zone.
Comparing Apples . . .
If we can agree that a comparative analysis of therapeutic
studies is a useful exercise, then even in incurable diseases,
we should agree on some ground rules. In mesothelioma,
despite the atrocious staging systems,17 there is uniform
agreement that lymph node involvement is prognostically
important. Therefore, is it unreasonable to state that, even if
one does not perform an EPP, the disease should be staged
with a lymph node sampling or dissection in all of the
cases? As reported by Lee and associates in their report, the
lack of staging information on 38% of the patients presents
problems of potential understaging, which make it ex-
tremely difficult to compare their study with established
studies. Nevertheless, the authors state that their results are
as good as Sugarbaker’s (18.1-month vs 19-month median
survival). Closer inspection of the two series reveals that in
Sugarbaker’s series, fully 40 (23%) of 176 patients had
extrapleural lymph node involvement16 compared with 12%
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in the series reported by Lee and colleagues. In reality, no
comparisons can be made because we really do not know
what the true stage of 38% of the patients in the Lee study
is, and there are no subset data regarding the results of the
18 patients with stage I disease. This is a painful lesson that
I have learned, and after having been guilty of inadequate
lymph node staging in my first 95 mesothelioma resec-
tions,18 I now perform mediastinal lymph node dissections
in all of my P/Ds and EPPs. I believe that more accurate
staging in protocols for mesothelioma decreases demo-
graphic heterogeneity. Moreover, if it is true that gene or
proteomic profiling for this disease will be a more accurate
way to define outcomes,19,20 it will be absolutely necessary
to have accurate staging data.
Follow-up
There are no standards with regard to the radiologic fol-
low-up of patients having surgery for mesothelioma, and
this is an issue that is not readily dealt with in the literature.
Sugarbaker and associates16 use 3 to 4-month follow-up
schedules with CT documentation of progression. Similar
follow-up schedules are used by other investigators.10 Why
is this important? Obviously, if the efficacy of therapy is
measured in mesothelioma as a prolongation of time to
progression, then it would behoove investigators to be on
the same wavelength with regard to follow-up schedules
and methods of follow-up (see “Comparing Apples. . .”). In
a series of 49 patients with mixed histology, mixed stage
pleural mesotheliomas having EPP, Baldini and cowork-
ers21 reported a 19-month median time to first recurrence in
a series of patients operated on in Boston, 29% of whom had
extrapleural lymph node involvement. The median progres-
sion-free survival in the Lee series, with 12% documented
N2 disease, all of whom had P/D, was 12.2 months. What is
even more disturbing about this shorter time to progression
in the Lee study is that the follow-up was performed with
“chest radiographs every 3 to 4 months with CT investiga-
tion of evolving abnormalities.” The lack of sensitivity of
chest radiographs in the visualization of pleural abnormal-
ities could falsely prolong the time to progression, and it is
not unusual to see evolving disease deep in the costophrenic
angles in an asymptomatic patient after resection without
changes in the chest x-ray film.
Adjuvant Therapies
When surgeons talk about adjuvant therapies that add nov-
elty to surgical resections for mesothelioma, they almost
always talk geography . . . New York, Boston, Detroit, Be-
thesda, Seattle, Los Angeles, San Francisco, and so on. This
reflects a commonality of interest as well as commonality of
frustration, and it also represents unique technologies that
are not commonly available. IORT and IMRT, as described
by Lee’s group, may actually be more available than other
technologies at a number of institutions, but even the au-
thors of this report are frustrated by the lack of efficacy. We
are all flailing and failing with this disease, maybe less than
in the past, and we are not organized to combat it as we are
in non–small cell lung cancer. In fact, the efforts in me-
sothelioma are similar to the early efforts in the mid-1980s
with phase II trials of induction therapy for lung cancer.
Meaningful, large-scale trials can be performed in me-
sothelioma, and our medical oncologic colleagues have
reported a randomized clinical trial comparing pemetrexed
(Alimta) and cisplatinum to cisplatinum alone in more than
446 patients accrued over 20 months.22 Mesothelioma is not
going away. More than 250,000 new cases are projected
over the next 30 years in Western Europe alone.23 A col-
laborative effort, independent of but encompassing all ge-
ographies, which combines uniform, objectively docu-
mented cytoreduction with a simple, yet promising and
available regimen is what is needed to answer therapeutic
and biologic questions in this disease.
Surgeons are eternal optimists, and believe me, this dis-
ease needs some optimists with good ideas. Got any?
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